Form 4: BioCardia Director Marvin Slosman Granted Stock Options

BioCardia Director Marvin Slosman was granted 12,000 stock options with an exercise price of $1.37, vesting over one year.

Summary

• Marvin Slosman, a Director of BioCardia, Inc. (BCDA), was granted 12,000 stock options.
• The transaction date for the grant was December 8, 2025.
• Each option has an exercise price of $1.37.
• The options are for the right to buy 12,000 shares of BioCardia Common Stock.
• The options will vest 100% on the one-year anniversary of the grant date, December 8, 2025, provided Mr. Slosman continues as a service provider.
• The expiration date for these options is December 8, 2035.
• Following this transaction, Mr. Slosman beneficially owns 12,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The grant of options is a standard compensation practice that aligns director interests with shareholders, which is generally viewed favorably. There are no immediate negative implications, but also no extraordinary positive news beyond routine compensation.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term performance.
• The options have a 10-year expiration period, providing a long window for potential value realization.

Risks

• The options are subject to a vesting condition, requiring the Reporting Person to continue as a service provider for one year from the grant date to become exercisable.
• The value of the options is dependent on the future stock price of BioCardia, Inc. exceeding the exercise price of $1.37.

Future Outlook

The grant of stock options with a one-year vesting period suggests an expectation of continued service from Director Marvin Slosman and aims to incentivize his long-term commitment and contribution to BioCardia's performance.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and broader corporate sectors. It serves as a form of equity compensation designed to attract and retain talent, align the interests of directors with those of shareholders, and incentivize long-term value creation. The specific terms, such as exercise price and vesting schedule, are typically determined by the company's compensation committee based on market practices and individual performance considerations.

Comparison to Industry Standards

• Granting stock options to non-employee directors is a standard compensation practice across various industries, including biotechnology, to align their interests with shareholders.
• A 10-year expiration period for stock options is typical for long-term incentive plans.
• One-year cliff vesting, as seen here, is a common vesting schedule for director equity grants, ensuring a minimum period of service.

Related Party Transactions

• The grant of stock options to Marvin Slosman, a Director of BioCardia, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant aims to align the director's long-term interests with shareholder value creation. Dilution from potential future exercise is a consideration, but typical for equity compensation.
• Employees: No direct impact on general employees is indicated by this filing.
• Management: The grant reinforces the compensation structure for key leadership roles.

Next Steps

• The stock options will vest 100% on December 8, 2025, provided Marvin Slosman continues as a service provider.
• Marvin Slosman may choose to exercise the options at any time after vesting and before the expiration date of December 8, 2035, subject to company policy and blackout periods.

Key Dates

Keywords

BioCardia, BCDA, stock option, director compensation, insider transaction, Form 4, equity grant